Endogenous Anticoagulants and the Role of Heparin in the Treatment of Severe Sepsis

  • C. J. Wiedermann
  • C. Pechlaner
Conference paper


New treatments for severe sepsis have yielded disappointing results in numerous trials conducted in the past 20 years. The interventions tested improved survival only marginally, if at all. Some were associated with unexpected toxicities. Not a single new agent had been introduced into clinical practice until recently [1–4].


Severe Sepsis Disseminate Intravascular Coagulation Disseminate Intravascular Coagulation Tissue Factor Pathway Inhibitor Drotrecogin Alfa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Graf J, Doig GS, Cook DJ, Vincent JL, Sibbald WJ (2002) Randomized, controlled clinical trials in sepsis: has methodological quality improved over time? Crit Care Med 30: 461 - 472PubMedCrossRefGoogle Scholar
  2. 2.
    Marshall JC (2000) Clinical trials of mediator-directed therapy in sepsis: what have we learned? Intensive Care Med 26 (suppl 1): S75 - S83PubMedCrossRefGoogle Scholar
  3. 3.
    Natanson C, Esposito CJ, Banks SM (1998) The sirens’ songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 26: 1927 - 1931PubMedCrossRefGoogle Scholar
  4. 4.
    Opal SM, Cross AS (1999) Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 13: 285-297Google Scholar
  5. 5.
    Bernard GR, Vincent JL, Laterre PF, et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699 - 709PubMedCrossRefGoogle Scholar
  6. 6.
    Angus DC, Laterre P-F, Helterbrand J, Ball D, Garg R, Bernard G (2002) The effects of drotrecogin alfa (activated) on long-term survival after sepsis. Annual Meeting of the American College of Chest Physicians, November 2-7, 2002, San Diego, CA, Abstract 5144Google Scholar
  7. 7.
    Bernard GR, Macias WL, Vincent J-L (2002) Drotrecogin alfa (activated) cumulative safety update. Annual Meeting of the American College of Chest Physicians, November 2-7, 2002, San Diego, CA, Abstract 5141Google Scholar
  8. 8.
    Bernard GR, Ely EW, Wright TJ, et al (2001) Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29: 2051 - 2059PubMedCrossRefGoogle Scholar
  9. 9.
    Warren HS, Suffredini AF, Eichacker PQ, Munford RS (2002) Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 347: 1027 - 1030PubMedCrossRefGoogle Scholar
  10. 10.
    Anti-Infective Advisory Committee. FDA briefing document: drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] Xigris. BLA #125029/0. Rockville, Md.: Food and Drug Administration, September 12, 2001. (Accessed November 30, 2002, at /briefing/3797b 1_02_FDAbriefing.pdfGoogle Scholar
  11. 11.
    Bernard GR, Margolis B, Shanies H, et al (2002) Efficacy and safety of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis: Report from a single-arm open-label trial in the United States. Annual Meeting of the American College of Chest Physicians, November 2-7, 2002, San Diego, CA, Abstract S142Google Scholar
  12. 12.
    Warren BL, Eid A, Singer P, et al (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286: 1869 - 1878PubMedCrossRefGoogle Scholar
  13. 13.
    Rublee D, Opal SM, Schramm W, Keinecke HO, Knaub S (2002) Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial. Crit Care 6: 349 - 356PubMedCrossRefGoogle Scholar
  14. 14.
    Vervloet NG, Thijs LG, Hack CE (1998) Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemostas 24: 33 - 34CrossRefGoogle Scholar
  15. 15.
    Levi M, ten Cate H (1999) Disseminated intravascular coagulation. N Engl J Med 341: 586592Google Scholar
  16. 16.
    Bock SC, Harris JF, Balazs I, et al (1985) Assignment of the human antithrombin III structural gene to chromosome lq 23-25. Cytogenet Cell Genet 39: 67 - 74PubMedCrossRefGoogle Scholar
  17. 17.
    Opal SM, Kessler CM, Roemisch J, Knaub S (2002) Antithrombin, heparin, and heparan sulfate. Crit Care Med 30 (suppl): S325 - S331PubMedCrossRefGoogle Scholar
  18. 18.
    Wiedermann CJ, Romisch J (2002) The anti-inflammatory actions of antithrombin - a review. Acta Med Austriaca 29: 89 - 92PubMedCrossRefGoogle Scholar
  19. 19.
    Iba T, Kidokoro A (2002) High-dose antithrombin therapy for sepsis: mechanisms of action. Shock 18: 389 - 394PubMedCrossRefGoogle Scholar
  20. 20.
    Eisele B, Lamy M, Thijs LG, et al (1998) Anti-thrombin III in patients with severe sepsis: a randomized, placebo-controlled, double-blind, multicenter trial plus a meta-analysis on all randomized-placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 24: 663 - 672PubMedCrossRefGoogle Scholar
  21. 21.
    Rivers E, Nguyen B, Haystad S, et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368 - 1377PubMedCrossRefGoogle Scholar
  22. 22.
    Levi M (2001) Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. J Crit Care 16: 167 - 177PubMedCrossRefGoogle Scholar
  23. 23.
    Opal SM (2001) Clinical impact of novel anticoagulation strategies in sepsis. Curr Opin Crit Care 7: 347 - 353PubMedCrossRefGoogle Scholar
  24. 24.
    Healy DP (2002) New and emerging therapies for sepsis. Ann Pharmacother 36: 648 - 654PubMedCrossRefGoogle Scholar
  25. 25.
    Ahmed T, Gonzalez BJ, Danta I (1999) Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin. Am J Respir Crit Care Med 160: 576 - 581PubMedCrossRefGoogle Scholar
  26. 26.
    Coalson JJ, Benjamin B, Archer LT, et al (1978) Prolonged shock in the baboon subjected to infusion of E. coli endotoxin. Circ Shock 5: 423 - 437Google Scholar
  27. 27.
    Wheeler AP, Bernard GR (1999) Treating patients with severe sepsis. N Engl J Med 340: 207 - 214PubMedCrossRefGoogle Scholar
  28. 28.
    Corrigan JJ (1977) Heparin therapy in bacterial septicemia. J Pediatr 91: 695 - 700PubMedCrossRefGoogle Scholar
  29. 29.
    Schipper HG, Jenkins CSP, Kahl LH, et al (1978) Antithrombin III transfusion in disseminated intravascular coagulation. Lancet 1: 854 - 856PubMedCrossRefGoogle Scholar
  30. 30.
    Davidson BL, Geerts WH, Lensing AW (2002) Low-dose heparin for severe sepsis. N Engl J Med 347: 1036 - 1037PubMedCrossRefGoogle Scholar
  31. 31.
    Langer M, Riccardi F, Piovella F, et al (2002) Use of anticoagulants in patients with sepsis. JAMA 287: 448 - 449PubMedCrossRefGoogle Scholar
  32. 32.
    Kaneider NC, Reinisch CM, Dunzendorfer S, Romisch J, Wiedermann CJ (2002) Syndecan4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J Cell Sci 115: 227 - 236PubMedGoogle Scholar
  33. 33.
    Hoffmann JN, Vollmar B, Laschke MW, et al (2002) Adverse effect of heparin on anti-thrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 88: 242 - 252PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • C. J. Wiedermann
  • C. Pechlaner

There are no affiliations available

Personalised recommendations